Mansoor Raza Mirza
About
Mansoor Raza Mirza is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology.
According to data from OpenAlex, Mansoor Raza Mirza has authored 228 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Reproductive Medicine, 109 papers in Oncology and 82 papers in Obstetrics and Gynecology. Recurrent topics in Mansoor Raza Mirza's work include Ovarian cancer diagnosis and treatment (130 papers), Endometrial and Cervical Cancer Treatments (81 papers) and PARP inhibition in cancer therapy (70 papers). Mansoor Raza Mirza is often cited by papers focused on Ovarian cancer diagnosis and treatment (130 papers), Endometrial and Cervical Cancer Treatments (81 papers) and PARP inhibition in cancer therapy (70 papers). Mansoor Raza Mirza collaborates with scholars based in Denmark, United States and Italy. Mansoor Raza Mirza's co-authors include Carien L. Creutzberg, Frédéric Amant, Jonathan A. Ledermann, Nicoletta Colombo, Isabelle Ray‐Coquard, Martin Koskas, Ignace Vergote, Antonio González-Martı́n, Ana Oaknin and Éric Pujade-Lauraine and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.
In The Last Decade
Mansoor Raza Mirza
216 papers receiving 6.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mansoor Raza Mirza Denmark | 34 | 3.6k | 2.6k | 2.4k | 1.3k | 952 | 228 | 6.4k | ||
| Paul DiSilvestro United States | 33 | 3.9k 1.1× | 2.0k 0.8× | 2.6k 1.1× | 1.3k 1.0× | 1.2k 1.2× | 159 | 6.4k | ||
| Antonio González-Martı́n Spain | 40 | 3.5k 1.0× | 4.1k 1.6× | 1.7k 0.7× | 1.4k 1.1× | 1.1k 1.2× | 307 | 7.5k | ||
| Michael W. Sill United States | 36 | 2.6k 0.7× | 2.4k 0.9× | 2.4k 1.0× | 2.0k 1.6× | 974 1.0× | 110 | 6.2k | ||
| Shannon N. Westin United States | 39 | 2.1k 0.6× | 1.8k 0.7× | 2.1k 0.9× | 1.5k 1.2× | 727 0.8× | 276 | 5.4k | ||
| Alexandra Léary France | 38 | 2.6k 0.7× | 3.5k 1.3× | 2.4k 1.0× | 2.0k 1.6× | 879 0.9× | 280 | 7.5k | ||
| Helen Huang United States | 30 | 4.8k 1.3× | 2.9k 1.1× | 2.6k 1.1× | 1.3k 1.0× | 2.7k 2.8× | 68 | 8.1k | ||
| John T. Soper United States | 51 | 3.5k 1.0× | 1.9k 0.8× | 3.6k 1.5× | 1.3k 1.0× | 1.5k 1.6× | 191 | 8.3k | ||
| John O. Schorge United States | 46 | 2.9k 0.8× | 1.1k 0.4× | 2.4k 1.0× | 1.4k 1.1× | 1.3k 1.4× | 194 | 5.9k | ||
| D. Scott McMeekin United States | 40 | 2.8k 0.8× | 1.3k 0.5× | 3.3k 1.4× | 1.1k 0.9× | 1.2k 1.3× | 121 | 5.6k | ||
| Werner Meier Germany | 32 | 3.2k 0.9× | 3.3k 1.3× | 866 0.4× | 1.6k 1.3× | 1.1k 1.2× | 166 | 5.8k |
Countries citing papers authored by Mansoor Raza Mirza
Since
Specialization
Citations
This map shows the geographic impact of Mansoor Raza Mirza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mansoor Raza Mirza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mansoor Raza Mirza more than expected).
Fields of papers citing papers by Mansoor Raza Mirza
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mansoor Raza Mirza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mansoor Raza Mirza. The network helps show where Mansoor Raza Mirza may publish in the future.
Co-authorship network of co-authors of Mansoor Raza Mirza
This figure shows the co-authorship network connecting the top 25 collaborators of Mansoor Raza Mirza. A scholar is included among the top collaborators of Mansoor Raza Mirza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mansoor Raza Mirza. Mansoor Raza Mirza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Valabrega, Giorgio, Ignace Vergote, Debra L. Richardson, et al.. (2025). Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study. International Journal of Gynecological Cancer. 35(2). 100081–100081.
2.
Kristeleit, Rebecca, Mansoor Raza Mirza, Antonio González-Martı́n, et al.. (2025). DDRiver EOC 302: A Randomised Phase 2 Study Of Tuvusertib With Niraparib Or Lartesertib In Patients With Epithelial Ovarian Cancer That Has Progressed On Prior PARP Inhibitor Therapy. International Journal of Gynecological Cancer. 35(2). 101597–101597.
3.
Mariani, Luca, et al.. (2024). Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity. JCO Precision Oncology. 8(8). e2300483–e2300483.
4.
Nogueira‐Rodrigues, Angélica, et al.. (2024). Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes. International Journal of Gynecological Cancer. 34(8). 1263–1272.
5.
Jørgensen, Trine Lembrecht, Destin Black, David Cibula, et al.. (2024). Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. 42(16_suppl). 5607–5607.
6.
Girda, Eugenia, Vicky Makker, Christian Marth, et al.. (2024). A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer. Gynecologic Oncology. 190. S293–S294.
7.
Auranen, Annika, Lyndsay Willmott, David Cibula, et al.. (2024). 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups. ESMO Open. 9. 103537–103537.
8.
Mirza, Mansoor Raza, Destin Black, Antonella Savarese, et al.. (2024). 38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Open. 9. 103538–103538.
9.
Mirza, Mansoor Raza, Sudarshan Sharma, Jørn Herrstedt, et al.. (2023). 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S507–S507.
10.
Chase, Dana M., Line Bjørge, Robert L. Coleman, et al.. (2023). #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial. A8–A9.
11.
Vergote, Ignace, Mansoor Raza Mirza, Jalid Sehouli, et al.. (2022). 2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer. International Journal of Gynecological Cancer. 32. A64–A64.
12.
Mirza, Mansoor Raza, David M. O’Malley, Philipp Harter, et al.. (2022). 2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. International Journal of Gynecological Cancer. 32. A234–A234.
13.
Kacperczyk‐Bartnik, Joanna, Sara Nasser, Nicolò Bizzarri, et al.. (2022). 2022-RA-853-ESGO Analysis of the gender distribution among the invited speakers at European society of gynaecological oncology (ESGO) biannual congresses 2017, 2019, and 2021. International Journal of Gynecological Cancer. 32. A192–A193.
14.
Ángeles, Martina Aida, Félix Boria, Nicolò Bizzarri, et al.. (2022). Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative. International Journal of Gynecological Cancer. 33(1). 12–18.
15.
Sztupinszki, Zsófia, et al.. (2021). Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer. Clinical Cancer Research. 27(20). 5681–5687.
16.
Suh, Dong Hoon, Miseon Kim, Kyung-Hun Lee, et al.. (2018). Major clinical research advances in gynecologic cancer in 2017. Journal of Gynecologic Oncology. 29(2). e31–e31.
17.
Oonk, Maaike H.M., François Planchamp, Peter Baldwin, et al.. (2017). European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. International Journal of Gynecological Cancer. 27(4). 832–837.
18.
Mirza, Mansoor Raza, Lucy Gilbert, Michel Fabbro, et al.. (2017). The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial. Annals of Oncology. 28. v331–v332.
19.
Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. Journal of Clinical Oncology. 32(13). 1302–1308.
20.
Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer. Obstetrical & Gynecological Survey. 69(7). 402–404.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul DiSilvestro Breakdown of academic impact, for papers by Antonio González-Martı́n Breakdown of academic impact, for papers by Michael W. Sill Breakdown of academic impact, for papers by Shannon N. Westin Breakdown of academic impact, for papers by Alexandra Léary Breakdown of academic impact, for papers by Helen Huang Breakdown of academic impact, for papers by John T. Soper Breakdown of academic impact, for papers by John O. Schorge Breakdown of academic impact, for papers by D. Scott McMeekin Breakdown of academic impact, for papers by Werner Meier